VERY-RARE CANCERBone TumorWHO 5th Edition Classification

Chordoma

Very Rare Malignancy (1–5 cases per 1,000,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

A slow-growing bone tumour arising from remnants of the embryonic notochord, occurring along the midline of the skull base, mobile spine and sacrum. It grows insidiously and encases critical nerves and vessels, which makes complete removal the single most important - and most technically demanding - determinant of outcome.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Do not biopsy a suspected chordoma outside a sarcoma centre - seeding risk
Who It Affects

Adults, median 50-60; the poorly differentiated form affects children

Annual Incidence

Approximately 0.8 per million per year

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Headache, double vision or difficulty swallowing with skull-base tumours
Low back or tailbone pain with sacral tumours, often for years
Bowel or bladder dysfunction
Numbness, weakness or sciatica-like pain
A palpable presacral mass on rectal examination

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

Brachyury (TBXT) nuclear expressionTBXT duplicationCDKN2A lossSMARCB1 loss - poorly differentiated variant

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

En bloc surgical resection with wide margins - the primary determinant of cure

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Proton beam or carbon ion radiotherapy, which permit high doses near neural structures

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Conventional high-dose photon radiotherapy where particle therapy is unavailable

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Systemic therapy in advanced disease - imatinib, EGFR inhibitors (trial setting)

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Specialist multidisciplinary review before any biopsy, to avoid tract seeding

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Median survival is around 7-8 years, with five-year survival near 65-70%. Local recurrence, not distant spread, is the usual cause of death. Outcomes are markedly better at high-volume centres.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Brachyury (TBXT) is the lineage-defining driver and is the target of vaccine and degrader programmes; the Chordoma Foundation coordinates an international trial network.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Chordoma

Browse All Oncologists

Dr. Ian F. Pollack

Neurosurgeon

30+ yrs exp

University of Pittsburgh

Pittsburgh, USA

Skull-base SurgeryChordomaProton Therapy
Vetted DirectoryConsult Specialist

Dr. Iqbal Muttaqin

Neurosurgeon

20+ yrs exp

NCCS Singapore

Singapore, Singapore

Spine/Skull-base TumorsChordomaAdvanced Techniques
Vetted DirectoryConsult Specialist

Prof. Ralph Weber

Orthopedic Surgeon

25+ yrs exp

Charité Berlin

Berlin, Germany

Chordoma ResectionSacral/Pelvic SitesProton Centers
Vetted DirectoryConsult Specialist

Dr. S. Karunakaran

Neurosurgeon

20+ yrs exp

Apollo Hospitals

Chennai, India

Skull-base SurgeryClival/Sacral ChordomaProton Therapy
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

very-rare

Angioimmunoblastic T-cell Lymphoma (AITL)

very-rare

Appendiceal Carcinoma

very-rare

Esthesioneuroblastoma

very-rare

Adenoid Cystic Carcinoma (ACC)

Independent Tumor Board Review

Facing a Diagnosis of Chordoma?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult